Literature DB >> 33927087

Prevalence of HIV/hepatitis B and HIV/hepatitis C coinfection among people of East, South, Central and West African ancestry in the United Kingdom.

Rachel Hung1,2, Nisha Patel1, Julie Fox2,3, Catherine Cosgrove4, Sarah L Pett5,6, Fiona Burns6,7, Andrew Ustianowski8, Melanie Rosenvinge9, Sanjay Bhagani6,7, Geoff Dusheiko1,6, Kate Childs1, Frank A Post1,2.   

Abstract

Regional variability in the prevalence of hepatitis B (HBV) and C (HCV) is reported in sub-Saharan Africa, although data for people with HIV are sparse. We determined the prevalence of HBV/HCV in 2473 people of African ancestry with HIV in the UK. Overall, 6.2% were co-infected with HBV and 1.3% with HCV. Central [adjusted odds ratio (aOR) 2.40 (95% confidence interval (CI) 1.23--4.67) and West [2.10 (1.29-3.41)] African ancestry was associated with HBV and Central [6.98 (2.00-24.43)] African ancestry with HCV.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh：

Year:  2021        PMID： 33927087      PMCID： PMC7611292          DOI： 10.1097/QAD.0000000000002929

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  9 in total

1.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity.

Authors:  J J Ott; G A Stevens; J Groeger; S T Wiersma
Journal:  Vaccine       Date:  2012-01-24       Impact factor: 3.641

Review 2.  Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis.

Authors:  Roos E Barth; Quirine Huijgen; Jantjie Taljaard; Andy I M Hoepelman
Journal:  Int J Infect Dis       Date:  2010-09-25       Impact factor: 3.623

3.  High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.

Authors:  Belinda V Chihota; Gilles Wandeler; Roma Chilengi; Lloyd Mulenga; Raymond T Chung; Debika Bhattacharya; Mathias Egger; Michael J Vinikoor
Journal:  J Infect Dis       Date:  2020-01-02       Impact factor: 5.226

4.  Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.

Authors:  A Boyd; R Moh; S Maylin; M Abdou Chekaraou; N Mahjoub; D Gabillard; X Anglaret; S P Eholié; C Delaugerre; C Danel; F Zoulim; K Lacombe
Journal:  J Viral Hepat       Date:  2018-05-09       Impact factor: 3.728

Review 5.  Prevalence of HIV and hepatitis B virus co-infection in sub-Saharan Africa and the potential impact and program feasibility of hepatitis B surface antigen screening in resource-limited settings.

Authors:  Lara Stabinski; Siobhan OʼConnor; Matthew Barnhart; Rebecca J Kahn; Tiffany E Hamm
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

Review 6.  Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa.

Authors:  Philippa C Matthews; Anna Maria Geretti; Philip J R Goulder; Paul Klenerman
Journal:  J Clin Virol       Date:  2014-06-05       Impact factor: 3.168

7.  Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C.

Authors:  Kate Childs; Christopher Davis; Mary Cannon; Sarah Montague; Ana Filipe; Lily Tong; Peter Simmonds; Donald Smith; Emma C Thomson; Geoff Dusheiko; Kosh Agarwal
Journal:  J Hepatol       Date:  2019-08-07       Impact factor: 25.083

Review 8.  Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Alexander J Stockdale; Mas Chaponda; Apostolos Beloukas; Richard Odame Phillips; Philippa C Matthews; Athanasios Papadimitropoulos; Simon King; Laura Bonnett; Anna Maria Geretti
Journal:  Lancet Glob Health       Date:  2017-10       Impact factor: 26.763

9.  Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa.

Authors:  Patrick A Coffie; Boris K Tchounga; Guillaume Bado; Mathieu Kabran; Daouda K Minta; Gilles Wandeler; Geoffrey S Gottlieb; François Dabis; Serge P Eholie; Didier K Ekouevi
Journal:  BMC Infect Dis       Date:  2017-07-04       Impact factor: 3.090
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.